Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

BioInvent International AB: BioStock: BioInvent secures FDA Fast Track Designation for BI-1808

BioInvent International

BioInvent has published its Q1 2025 interim report, outlining progress in its clinical programmes. Adding to the momentum, the FDA has granted Fast Track Designation to BI-1808 for the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, subtypes of cutaneous T-cell lymphoma. We reached out to BioInvent's CEO, Martin Welschof, for a comment.

Read the interview at biostock.se:

https://www.biostock.se/en/2025/05/bioinvent-secures-fda-fast-track-designation-for-bi-1808/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.